Over recent years, Vaxart experienced significant corporate evolution, marked by high public attention during the global health crisis for its experimental oral vaccine candidates, followed by subsequent normalization phases typical of clinical-stage biotech enterprises. As initial pandemic-era momentum shifted, the company refocused its scientific and clinical resources on advancing its core proprietary pipeline, particularly its norovirus and therapeutic influenza programs. Financially, the company has navigated the challenges common to early-stage biotechnology firms, managing capital-raising initiatives, executing clinical trials, and striving to bring its innovative oral pill technology closer to regulatory approval and commercial viability.